Quantcast

Abviva, Inc. Announces New Website

March 24, 2008

Abviva, Inc. (OTCBB: AVVA) today announced the Company launched its new website at www.abviva.com as part of the continued development of its breast cancer diagnostic business and the Mammastatin Serum Assay.

Abviva’s website is intended to be an informational resource for women and physicians to increase awareness and understanding of the benefits of early breast cancer detection and of the Mammastatin Serum Assay (MSA). In clinical studies, 98% of women with no history of breast cancer had normal or high levels of mammastatin in their MSA blood test. More importantly, 74% of women with a history of breast cancer had no mammastatin present or very low levels. These findings highlight the early detection benefits of the MSA.

Early detection is very important in the fight against breast cancer. Women diagnosed early generally have improved survival rates. The MSA test can be valuable for early detection of asymptomatic, undiagnosed women. Additionally, more women can have increased access to breast cancer screening with the MSA, especially in underserved areas and populations, because it is a simple blood test. The Company intends to offer the MSA test later this year.

For more information go to www.breastcancerdiagnostic.com.

About Abviva, Inc.

Abviva, Inc. is a biomedical company established to develop and commercialize diagnostic and therapeutic products from Mammastatin, a breast cancer growth inhibitory protein that is normally present in healthy women and absent in most women with breast cancer.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe,”"estimate,”"project,”"expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.




comments powered by Disqus